Johnson & Johnson (JNJ)vsQ32 Bio Inc (QTTB)
JNJ
Johnson & Johnson
$276.22
+1.43%
HEALTHCARE · Cap: $657.68B
QTTB
Q32 Bio Inc
$9.25
+4.52%
HEALTHCARE · Cap: $257.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 184754% more annual revenue ($99.33B vs $53.74M). QTTB leads profitability with a 62.9% profit margin vs 16.2%. QTTB trades at a lower P/E of 2.8x. QTTB earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
QTTB
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JNJ.
Margin of Safety
+87.5%
Fair Value
$30.73
Current Price
$9.25
$21.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 32 in profit
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 39.9%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : QTTB
The strongest argument for QTTB centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 62.9% and operating margin at 39.9%.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : QTTB
The primary concerns for QTTB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while QTTB is a value play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 54/100), backed by strong 16.2% margins. QTTB offers better value entry with a 87.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Q32 Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization. Leveraging its proprietary technology platform, the company is building a robust pipeline of therapeutic candidates designed to restore immune balance and tackle significant unmet medical needs. Guided by a seasoned management team and reinforced by strategic collaborations, Q32 Bio is well-positioned to make impactful contributions to healthcare and generate substantial long-term value for its shareholders through dedicated research and development initiatives.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?